Stock Rating Upgrade
The Value Trend Rating for ADMA Biologics Inc (NASDAQ: ADMA) improved recently from C to B reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are included in our next report.
Recent Price Action
ADMA Biologics Inc (NASDAQ: ADMA) stock enjoyed a large increase of 3.0% on 3/1/24. The stock closed at $5.52. Moreover, above average trading volume at 136% of normal accompanied the advance. The stock has been exceptionally strong relative to the market over the last nine months and has risen 4.9% during the last week.
Current PriceTarget Research Rating
ADMA’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to be a major Value Builder.
ADMA Biologics has a current Value Trend Rating of B (Positive). This VT Rating improved in recent days from C previously. With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. ADMA Biologics has a neutral Appreciation Score of 46 but a very high Power Rating of 90, producing the Positive Value Trend Rating.
Be the first to comment